SCHEMBL15030482

SCHEMBL15030482

Cc1cccn(CC(=O)c2ccccc2)c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPT P10636 3/20 0.51
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
THRB P10828 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MGAM O43451 1/20 0.46
AMY1A P0DUB6 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
POLB P06746 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
ALOX12 P18054 1/20 0.44
RECQL P46063 1/20 0.44
RAB9A P51151 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16806629 0.89 KDM4E (0.54) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030308 0.89 MMP14 (0.50) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030297 0.88 ALDH1A1 (0.53) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030298 0.88 RXFP1 (0.60) KMT2AALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL15030559 0.87 KDM4E (0.51) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030280 0.86 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL16806662 0.85 ALDH1A1 (0.45) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030431 0.84 ALDH1A1 (0.44) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030485 0.84 MAPT (0.52) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL15030415 0.84 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
EP-2789607-B1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2018-02-07 EP disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 EP disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MEN1 483/4885KMT2A 2609/4885ALDH1A1 327/4885
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof PNPO, PDXK, PLPBP MEN1 480/4885KMT2A 2495/4885ALDH1A1 368/4885
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION PF4, F2, PFKP MEN1 2104/4885KMT2A 4643/4885ALDH1A1 1362/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MEN1 483/4885KMT2A 2609/4885ALDH1A1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.